TRITON3: PFS Boost With Rucaparib For BRCA-Positive Metastatic CRPC
From 2023 ASCO GU Cancers Symposium:
The use of rucaparib alongside a second-generation androgen receptor pathway inhibitor improves the outcome of patients with metastatic castration-resistant prostate cancer